Patents Assigned to College
-
Patent number: 11246845Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.Type: GrantFiled: December 18, 2020Date of Patent: February 15, 2022Assignees: Io Therapeutics, Inc., Trustees of Dartmouth CollegeInventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
-
Patent number: 11248029Abstract: Proteins, nucleic acids encoding the proteins, compositions comprising the proteins, and methods are provided. The proteins have the ability to be self-targeted to ICAM-1 and, if desired, enzymatically-released at acidic pH. The ICAM-1-targeting peptides are provided as single copies or multiples repeats, and can be separated by linkers from the enzyme segment, from which the ICAM-1 targeting peptides can be released, if desired, at acidic pH. These fusion proteins enhance the activity of the enzyme segment within or liberated from the fusion protein, and provide increased recognition and targeting of diseased organs, transport from the bloodstream across the endothelium into said diseased organ, and intracellular uptake and lysosomal trafficking by cells in them, both in peripheral tissues and the central nervous system. Representative nucleotide and amino acid sequences of these fusion proteins, as well as in vitro, cellular, and in vivo animal data are provided.Type: GrantFiled: November 18, 2020Date of Patent: February 15, 2022Assignee: University of Maryland, College ParkInventors: Silvia Muro, Jing Chen, Melani Solomon, Kevin Gray
-
Patent number: 11248313Abstract: This present disclosure provides methods for utilizing such forces in when generating nanofibrillar constructs with engineered morphology from the nano- to macro-scales. Using for example, a biopolymer silk fibroin as a base material, patterns an intermediate hydrogel were generated within a deformable mold. Subsequently, mechanical tension was introduced via either hydrogel contraction or mold deformation, and finally a material is reentrapped in this transformed shape via beta-sheet crystallization and critical point drying. Topdown engineered anchorages, cables, and shapes act in concert to mediate precision changes in nanofiber alignment/orientation and a macroscale form of provided nanofibrillar structure. An ability of this technique to engineer large gradients of nano- and micro-scale order, manipulate mechanical properties (such as plasticity and thermal transport), and the in-situ generation of 2D and 3D, multi-tiered and doped, nanofibrillar constructs was demonstrated.Type: GrantFiled: August 1, 2017Date of Patent: February 15, 2022Assignee: Trustees of Tufts CollegeInventors: Fiorenzo G. Omenetto, Peter Tseng
-
Publication number: 20220039362Abstract: A genetically modified non-human animal comprising a genome containing an endogenous non-human ACE2 locus genetically modified to encode a complete human ACE2 gene. According to a further embodiment the genome is genetically modified to encode a second, a third, and a fourth complete human ACE2 gene, the human ACE2 gene is at least 85 percent identical to SEQ ID No: 1, the animal of is a mouse, the human ACE2 gene encodes six protein variants, an endogenous Tmprss2 gene is unmodified, a LoxP gene flanks each of a 5? and a 3? end of a nucleic acid sequence of the human ACE2 gene, and the human ACE2 gene is expressed in a lung, kidney, spleen, stomach, liver, intestine, heart, and skeletal muscle of the animal, and a cortex, striatum, middle brain, hippocampus, olfactory bulb, and cerebellum of a brain of the animal.Type: ApplicationFiled: August 23, 2021Publication date: February 10, 2022Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Xiaohong LU, Xinli TIAN
-
Publication number: 20220040207Abstract: Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.Type: ApplicationFiled: April 2, 2020Publication date: February 10, 2022Applicants: The University of Chicago, The United States of America as Represented by the Secretary Department of Health and Human Services, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center, Inc.Inventors: Julian SOLWAY, Nickolai DULIN, Marsha ROSNER, Gokhan MUTLU, Diane LUCI, David MALONEY, Chan Young PARK, Jeffrey FREDBERG, David MCCORMICK, Ramaswamy KRISHNAN
-
Publication number: 20220041552Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.Type: ApplicationFiled: October 25, 2021Publication date: February 10, 2022Applicants: President and Fellows of Harvard College, Children's Medical Center CorporationInventors: Bruce P. Bean, Clifford J. Woolf, Jinbo Lee, Sooyeon Jo, David P. Roberson, Sebastien Talbot
-
Publication number: 20220040017Abstract: A method of supporting a body part (16), comprising providing a device (100) comprising: a first portion (105) configured to support a body part, wherein, in use, the body part applies a first pressure to the first portion in a first direction; means for detecting the first pressure; and a second portion (115) having means (212) for applying a second pressure to the body part in a second direction substantially perpendicular to the first direction; detecting the first pressure; determining the second pressure based on a user parameter; and applying the second pressure to the body part in the second direction at a pre-determined ratio relative to the first pressure using said means for applying the second pressure.Type: ApplicationFiled: September 12, 2019Publication date: February 10, 2022Applicant: Imperial College of Science, Technology and MedicineInventors: Spyridon MASOUROS, Grigorios GRIGORIADIS, Colin BOYLE
-
Publication number: 20220040222Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, dially disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.Type: ApplicationFiled: August 9, 2021Publication date: February 10, 2022Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Christopher KEVIL, Gopi K. Kolluru
-
Patent number: 11242515Abstract: Disclosed herein are methods for the isolation and purification of a botulinum neurotoxin (BoNT) protein, or a polypeptide comprising a receptor binding domain of BoNT, from a solution. The method comprises contacting the solution containing the protein or polypeptide to a matrix which has attached thereto a non-toxic non-hemagglutinin (NTNHA) under conditions appropriate for binding, washing the matrix to thereby remove unbound materials, and eluting the protein or polypeptide with a solution that dissociates the bound protein from the NTNHA. Conditions appropriate for binding are a pH of less than 7.5 (e.g, 6). Conditions appropriate for dissociation are a pH greater than or equal to 7.5 (e.g., 8). Compositions specific to the methods are also disclosed.Type: GrantFiled: May 16, 2017Date of Patent: February 8, 2022Assignee: President and Fellows of Harvard CollegeInventors: Min Dong, Sulyman Barkho, Liang Tao
-
Patent number: 11241442Abstract: The present invention relates to methods for treating cancer through combination therapy with a TRP channel antagonist and standard-of-care cancer agents.Type: GrantFiled: March 5, 2018Date of Patent: February 8, 2022Assignee: President and Fellows of Harvard CollegeInventors: Joan Siefert Brugge, Nobuaki Takahashi
-
Patent number: 11241170Abstract: A method and apparatus for monitoring arterial properties, including systolic and diastolic pressure levels, of a subject is provided, in which a hardware processor receives and analyzes ballistocardiogram (BCG) data of the subject. A non-transient computer readable medium, accessible by the hardware processor, contains instructions that, when executed by the hardware processor, identify features of the BCG waveform and determine the arterial properties therefrom. For example, a diastolic pressure level may be determined from a time interval between the ‘I’ and ‘J’ peaks of the waveform and a systolic pressure level determined from the amplitude difference between the ‘J’ and ‘K’ peaks of the waveform in combination with the ‘I-J’ time interval or amplitude difference. A physical mechanism for the BCG data is disclosed that enables other arterial properties of the subject to be determined from the BCG data alone or from the BCG data in combination with other measurements.Type: GrantFiled: April 6, 2018Date of Patent: February 8, 2022Assignees: University of Maryland, College Park, Board of Trustees of Michigan State University, Georgia Tech Research CorporationInventors: Chang-Sei Kim, Stephanie Lind-Ober Martin, Jin-Oh Hahn, Ramakrishna Mukkamala, Omer T. Inan
-
Publication number: 20220031157Abstract: A visual stimulus for a set of contrast cards is provided which comprises a hollow outer circle, opposing and identical first and second arc segment within the outer circle which are symmetrical about the vertical diameter of the outer circle, a first filled-in circle and a second filled-in circle being identical in diameter to the first filled-in circle, each residing on opposite ends of the horizontal diameter of the outer circle and each being equidistant from the center of the outer circle, a filled-in center element having a rotational center on the center of the outer circle, the center element being symmetrical about both the horizontal and vertical diameter of the outer circle.Type: ApplicationFiled: July 30, 2020Publication date: February 3, 2022Applicant: New England College of OptometryInventors: Dale Luisa MAYER, Barry S. KRAN
-
Publication number: 20220033785Abstract: The disclosure provides programmable methylation “writers” and demethylation “erasers” for editing the methylation state of RNA targets, e.g., an RNA transcriptome. In particular, the disclosure provides RNA methylation editor polynucleotide contracts and vectors comprising (i) an RNA programmable RNA binding domain (RNApRNAbd); and (ii) an effector domain, wherein the effector domain is capable of adding or removing a methyl group in an RNA. The disclosed RNA methylation editor constructs are capable of achieving limited off-target modifications in RNA molecules. Further, the disclosure provides methods for making and using the programmable methylation editors to modifying the methylation state of RNA. The disclosure further provides complexes comprising a methylation writer protein and a guide RNA molecule and complexes comprising a demethylation eraser protein and a guide RNA molecule.Type: ApplicationFiled: July 9, 2019Publication date: February 3, 2022Applicants: The Broad Institute, Inc., President and Fellows of Harvard CollegeInventors: David R. Liu, Christopher Gerard Wilson, Peter J. Chen
-
Patent number: 11236332Abstract: The present invention discloses a set of human microRNAs, or a primary transcript for such microRNAs, or a precursor of such microRNAs, or a mimic of such microRNAs or a combination thereof, and their use as medicaments for inducing proliferation of cardiomyocytes for the prevention and treatment of heart diseases associated with a loss of cardiomyocytes. The invention also relates to a method for screening microRNAs and biological and therapeutically active compounds for their ability to increase proliferation of cardiomyocytes.Type: GrantFiled: May 1, 2019Date of Patent: February 1, 2022Assignee: King's College LondonInventors: Mauro Giacca, Serena Zacchigna, Miguel Luis Cunha Mano, Ana Sofia Bregieiro Eulalio
-
Patent number: 11237109Abstract: The present disclosure relates to spatially modulating the light source used in microscopy. In some cases, a light source projects a sequence of two-dimensional spatial patterns onto a sample using a spatial light modulator. In some cases, the spatial patterns are based on Hadamard matrices. In some cases, an imaging device captures frames of image data in response to light emitted by the sample and orthogonal components of the image data are analyzed by cross-correlating the image data with the spatial pattern associated with each frame. A microscope may be calibrated by illuminating a sample with the sequence of spatial patterns, capturing image data, and storing calibration that maps each pixel of the spatial light modulator to at least one pixel of the imaging device.Type: GrantFiled: January 26, 2018Date of Patent: February 1, 2022Assignee: President and Fellows of Harvard CollegeInventors: Adam Ezra Cohen, Vicente Jose Parot
-
Patent number: 11235152Abstract: One aspect of the invention provides a computer-implemented method of conveying a visual image to a blind subject fitted with a visual prosthesis. The computer-implemented method includes: mapping a representation of a visual image onto a two-dimensional array of points having a resolution greater than or equal to an electrode resolution of the visual prosthesis; identifying one or more continuous paths along the mapped representation; and controlling the visual prosthesis to sequentially actuate electrodes along the one or more paths. Another aspect of the invention provides a system including: a visual prosthesis comprising multiple electrodes; and an imaging processing device in communication with the visual prosthesis. The imaging processing device can be programmed to receive an image and perform any of the methods described herein.Type: GrantFiled: March 5, 2019Date of Patent: February 1, 2022Assignee: Baylor College of MedicineInventors: Michael S. Beauchamp, Daniel Yoshor, William H. Bosking, III
-
Patent number: 11239404Abstract: A method for reducing switching losses and waveform distortion in a driver for a circuit with a capacitive load includes generating a variable pre-drive pulse to achieve zero voltage and zero-current switching of a high-side switch of the unfolding stage. A controller computes the variable pre-drive pulse with the controller, and a sense resistor in series with the power converter inductor detects a zero voltage switching condition point and/or a zero voltage switching condition point. The driver includes a power converter that receives an input voltage vin as input and generates a clean folded waveform as an output. An unfolding stage referenced to vin receives the clean folded waveform from the converter and unfolds the folded waveform into a full waveform.Type: GrantFiled: December 14, 2018Date of Patent: February 1, 2022Assignee: President and Fellows of Harvard CollegeInventor: Simon Chaput
-
Patent number: 11235972Abstract: The present disclosure provides, in some aspects, methods and compositions for producing nucleic acid nanostructures having little to no kinetic barriers to self-assembly.Type: GrantFiled: April 11, 2017Date of Patent: February 1, 2022Assignee: President and Fellows of Harvard CollegeInventors: Nikhil Gopalkrishnan, Thomas E. Schaus, Peng Yin
-
Patent number: 11236956Abstract: Methods and systems are disclosed which utilize liquid-philic surfaces and liquid-phobic surfaces to more safely and efficiently boil liquids and/or condense vapors. The methods and systems generally utilize two separated surfaces for nucleate boiling, where one of the surfaces is liquid-philic and the other is liquid-phobic. The methods and systems can utilize a condensing surface for condensing vapors, where the condensing surface can have liquid-philic regions and liquid-phobic regions.Type: GrantFiled: October 15, 2019Date of Patent: February 1, 2022Assignee: The Board of Regents for the Oklahoma Agricultural and Mechanical CollegesInventor: Prem Kumar Bikkina
-
Patent number: 11236359Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.Type: GrantFiled: February 12, 2016Date of Patent: February 1, 2022Assignee: President and Fellows of Harvard CollegeInventors: Prashant G. Mali, George M. Church, Luhan Yang